ADRB3 and obesity disorder: These observations raised interest in the development of compounds for the treatment of obesity and type 2 diabetes [122,123], but clinical studies [124,125] were disappointing due to poor selectivity of the drugs for the human β3-AR and different contributions of white and brown adipocytes in rodents and humans [126].